As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or weight loss. Dr. Brett Osborn and Dr. Sue Decotiis warn of potential risks.

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The future of the weight loss market might not revolve around GLP-1 drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

Researchers at Massachusetts General Hospital have discovered that meeting the weekly recommended physical activity levels, ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

Brookstone Capital Management cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 1.1% during the 3rd ...

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...